8-K: Xencor's XmAb819 Shows 25% ORR in Advanced ccRCC

Xencor announced initial Phase 1 results for XmAb819 in advanced clear cell renal cell carcinoma, demonstrating a 25% overall response rate and a well-tolerated safety profile.

Summary

• Initial Phase 1 dose-escalation study results for XmAb819 (ENPP3 x CD3) in 69 heavily pre-treated patients with advanced clear cell renal cell carcinoma (ccRCC) were presented.
• XmAb819 achieved a 25% Overall Response Rate (ORR) and a 70% Disease Control Rate (DCR) in 20 efficacy-evaluable patients within the target dose range.
• The drug was generally well-tolerated, with most adverse events being Grade 1 or 2, primarily cytokine release syndrome (CRS) and rash, occurring during initial priming doses.
• Early data from the Phase 1 dose-escalation study of XmAb541 (CLDN6 x CD3) in advanced ovarian cancer, endometrial cancer, and germ cell tumors showed evidence of anti-tumor activity, with some patients achieving partial response or stable disease.
• Xencor plans to initiate a pivotal study for XmAb819 in advanced ccRCC during 2027 and for XmAb541 in advanced solid tumors during 2027.

Sentiment

Score: 8

Explanation: The filing presents strong initial clinical data for XmAb819, meeting internal efficacy criteria in a challenging patient population, and outlines a clear path to pivotal studies. Early positive signals for XmAb541 also contribute to a positive outlook. While there were dose preparation errors, these have been identified and mitigation strategies are in place, with a new formulation planned. The overall progress and future plans are highly encouraging for the company's pipeline.

Positives

• XmAb819 demonstrated a 25% Overall Response Rate (ORR) and 70% Disease Control Rate (DCR) in heavily pre-treated ccRCC patients within the target dose range.
• XmAb819 exhibited a well-tolerated safety profile, with over 90% of patients reaching the target dose and a low 4% discontinuation rate due to adverse events.
• All five XmAb819 responders and 50% of all efficacy-evaluable patients in the target dose range remain on treatment as of the data cut-off.
• One patient with initial progressive disease on XmAb819 later showed a 47% tumor reduction and remains on treatment at week 30, suggesting potential for sustained benefit.
• XmAb819's pharmacokinetic profile supports convenient weekly to bi-weekly dosing.
• Early data for XmAb541 in ovarian, endometrial, and germ cell tumors shows evidence of anti-tumor activity, including partial responses and stable disease.
• Xencor's XmAb engineering technology has led to multiple commercialized antibodies by partners, providing potential future milestone and royalty funding.

Negatives

• Dose preparation errors in 18 patients led to 3-8 times higher than expected drug exposure during priming, resulting in a higher incidence of Grade 3 cytokine release syndrome (28% vs. 4% with correct dose).
• One dose-limiting toxicity of Grade 4 elevated liver enzymes was observed for XmAb819.
• Three patients (4%) discontinued XmAb819 treatment due to treatment-related adverse events, which included elevated liver enzymes and a non-fatal myocardial infarction.

Risks

• Potential delays in development timelines or negative preclinical or clinical trial results.
• Reliance on third parties for development efforts.
• Changes in the competitive landscape, including changes in the standard of care for treatment of diseases for which product candidates are being developed.
• The ability of publicly disclosed preliminary clinical trial data to support continued clinical development and regulatory approval for specific treatments.

Future Outlook

Xencor anticipates selecting a recommended Phase 3 dose for XmAb819 during 2026, with the initiation of a pivotal study in advanced ccRCC planned for 2027. They also expect to expand XmAb819 into additional tumor types and combination studies in 2026. For XmAb541, proof-of-concept dose escalation data is expected in 2025, with RP3D determination in 2026 and pivotal study initiation in advanced solid tumors in 2027. The company also highlights its pipeline of T-cell engagers and bispecific mechanisms in oncology and autoimmune diseases, supported by over 15 technology license partnerships that are potential sources of future milestone and royalty funding.

Management Comments

• "We are excited to be developing XmAb819 as a novel first-in-class ENPP3 T-cell engager that could potentially offer a much-needed new therapeutic modality for patients with advanced clear cell renal cell carcinoma and clinicians."
• "In our first clinical presentation of dose-escalation data, XmAb819 demonstrated compelling anti-tumor activity and a well-tolerated safety profile in very heavily pre-treated patients."
• "We are on-track with our first dose-expansion cohort now selected and are enrolling patients as we continue to dose escalate."
• "We are confident that we will be able to select a recommended Phase 3 dose during 2026 to support the initiation of our first pivotal study in advanced ccRCC during 2027."

Industry Context

The global renal cell carcinoma (RCC) market is projected to reach approximately $12 billion by 2030, with limited second-line and later treatment options beyond VEGF-TKIs. XmAb819 aims to address a significant unmet need for ~20,000 addressable U.S. patients who have progressed after IO + VEGF-TKI treatments. The evolving ccRCC landscape presents an opportunity for XmAb819 to redefine the standard of care in the second-line and later settings. For XmAb541, the market opportunity in CLDN6+ gynecological tumors (ovarian, endometrial, germ cell) is substantial, with global total addressable markets estimated at $4.5 billion for ovarian/endometrial and $4.2 billion for germ cell tumors by 2030/2035, respectively.

Comparison to Industry Standards

• XmAb819's 25% ORR in heavily pre-treated ccRCC patients compares favorably to other approved therapies in similar settings, such as Belzutifan (25% ORR in Phase 1 dose expansion, 23% in LITESPARK-005 study) and Tivozanib (18% ORR in TIVO-3 study).
• The patient population for XmAb819 was particularly challenging, with a median of 4 prior regimens, all having received prior checkpoint inhibitors and VEGF-TKIs, and 36% having received a HIF2 inhibitor, suggesting robust activity in a difficult-to-treat group.
• The potential bystander effect observed with XmAb819, where a patient with low ENPP3 expression (<25%) still achieved significant tumor reduction, suggests a broader therapeutic window or mechanism beyond direct antigen density.

Stakeholder Impact

• Shareholders/Investors: Positive clinical data and clear development timelines for key pipeline assets could increase investor confidence and potentially lead to share price appreciation. The identified dose preparation errors and their mitigation are important for risk assessment.
• Patients: XmAb819 offers a promising new therapeutic option for heavily pre-treated ccRCC patients with limited alternatives, potentially improving outcomes. XmAb541 also shows promise for patients with ovarian, endometrial, and germ cell tumors.
• Healthcare Providers: The data provides new information on potential future treatment options for advanced cancers, influencing clinical practice and treatment algorithms upon approval.
• Regulatory Authorities: The positive Phase 1 data supports continued clinical development and will be crucial for future regulatory submissions.

Next Steps

• Continue dose escalation for XmAb819 to identify IV Expansion Dose 2.
• Determine optimal IV or SC administration route and Recommended Phase 3 Dose (RP3D) for XmAb819 in 2026.
• Expand XmAb819 into additional tumor types and combination studies with standard of care in ccRCC in 2026.
• Initiate XmAb819 pivotal study as monotherapy in advanced ccRCC during 2027.
• Obtain Proof of Concept Dose Escalation (PoC DE) data for XmAb541 in 2025.
• Determine Recommended Phase 3 Dose (RP3D) for XmAb541 in 2026.
• Initiate XmAb541 pivotal study as monotherapy in advanced solid tumors during 2027.
• Roll out a low concentration XmAb819 formulation in 1H 2026 to eliminate dose preparation errors.

Key Dates

Recommendation

The initial Phase 1 results for XmAb819 in advanced ccRCC are highly encouraging, demonstrating a compelling 25% ORR and a well-tolerated safety profile in a very heavily pre-treated patient population where treatment options are limited. This efficacy compares favorably to existing therapies in similar settings. The clear roadmap to pivotal studies for both XmAb819 (2027) and XmAb541 (2027), coupled with early positive signals for XmAb541, significantly de-risks the company's oncology pipeline. While dose preparation errors were noted, they have been identified, addressed, and a new formulation is planned, indicating effective risk management. The company's proven XmAb engineering platform and existing partnerships further strengthen its long-term potential. These factors suggest a strong growth trajectory and significant upside for investors.

Keywords

Xencor, XNCR, XmAb819, ENPP3 x CD3, ccRCC, Renal Cell Carcinoma, T-cell Engager, Oncology, Clinical Trial, Phase 1, XmAb541, CLDN6 x CD3, Ovarian Cancer, Endometrial Cancer, Germ Cell Tumors, Biopharmaceutical, Antibody Engineering, Drug Development